Specialty biopharmaceuticals for inflammatory bowel disease
Strategic Profile
PALI-2108 is designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. Clinical data from the Phase 1b cohort in moderate-to-severe ulcerative colitis patients showed 100% achieved clinical response and 40% achieved clinical remission, with no serious adverse events; the company is advancing toward Phase 2 clinical studies in UC designed to evaluate clinical remission and response over 12 weeks.
Cyborg Score Rationale
Palisade Bio demonstrates promising early clinical data and a differentiated prodrug platform addressing a large IBD market, but faces typical clinical-stage risk including significant cash burn, development timelines, and regulatory approval uncertainties. The company's market capitalization of approximately $311M reflects early-stage valuation metrics with meaningful upside potential contingent on successful Phase 2 advancement.
Top Insights
PALI-2108 demonstrated 100% clinical response rate in Phase 1b UC cohort with no serious adverse events, supporting advancement to Phase 2 trials
Differentiated prodrug approach aims to improve pharmacology, tolerability and convenience compared to existing PDE4 inhibitors, targeting localized colon delivery
Strategic partnerships with Giiant Pharma and Newsoara Biopharma provide development and commercialization support for compound advancement
Clinical-stage company with minimal revenue generation; success dependent on Phase 2 data readout and eventual regulatory approval pathway
Named Competitors
Otezla (apremilast) — Established PDE4 inhibitor for inflammatory diseases
Humira (adalimumab) — TNF-alpha inhibitor for IBD and autoimmune conditions
Entyvio (vedolizumab) — Integrin antagonist for ulcerative colitis and Crohn's disease
Recent Developments
(May 2025) Presented Phase 1b preclinical efficacy data for PALI-2108 at Digestive Disease Week 2025 highlighting colon-specific bioactivation and PDE4B suppression
(April 2026) Announced partnership with Iterative Health to advance PALI-2108 development
(April 2026) Company website updated reflecting focus on next-generation PDE4 inhibitor prodrug platform for inflammatory and fibrotic diseases
Open the full interactive Palisade Bio, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.